WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) announced the
European Medicines Agency has accepted for review the Marketing Authorization
Application for linvoseltamab to treat adult patients with relapsed/refractory
multiple myeloma who have progressed after at least three prior therapies. The
company said its MAA is supported by data from a Phase 1/2 pivotal trial.

Linvoseltamab is an investigational bispecific antibody designed to bridge
B-cell maturation antigen on multiple myeloma cells with CD3-expressing T cells
to facilitate T-cell activation and cancer-cell killing.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX